A groundbreaking medical trial has found that administering stem cells to developing infants suffering from spina bifida while undergoing fetal surgery may represent a "important advancement" in treating birth defects.
Study Parameters and Security
The US-based trial focused on six unborn babies with the 'open' form of spina bifida. Surgeons applied mother's placental stem cells on the exposed area of the baby's spinal cord while the defect was being closed.
Importantly, the regenerative treatment proved to be secure. The study team reported that the cells did not cause tumors, hinder surgical recovery, or impede the resolution of associated brain abnormalities.
Positive Developments
Post-birth MRI scans showed a complete reversal of brainstem displacement in all six infants. This brain structure normalization is a key indicator for improved motor skills and quality of life.
"Should it enable more children to achieve ambulation who otherwise would not, it could establish itself as the new treatment paradigm," said the lead researcher. "The results are super exciting and pave the way for numerous possible innovative interventions."
Future Implications and Hope
Experts not involved in the trial indicated that further confirmation of these apparent benefits could announce a "fresh chapter" in in-utero treatment. The potential to improve nerve function impairment occurring during fetal development is viewed as a paradigm-shifting aim.
Especially significant would be better management of continence and digestive health, which are frequent complications for people affected by this disorder.
Future Directions
Despite this being a first-in-human effort was small in scale, its established security and encouraging indicators provide a strong foundation for broader investigative efforts. The integration of stem cell therapy with current in-utero repair procedures presents significant potential for improving the prognosis for babies yet to be born with this neural tube defect.